MedPath

Basiliximab

Generic Name
Basiliximab
Brand Names
Simulect
Drug Type
Biotech
CAS Number
179045-86-4
Unique Ingredient Identifier
9927MT646M
Background

A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha.

Indication

For prophylactic treatment of kidney transplant rejection

Associated Conditions
Rejection Acute Renal
Clinical Trials
Related News

Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases

Phase 2
Not yet recruiting
Conditions
Acute Graft Versus Host Disease
Malignant Hematologic Neoplasm
Interventions
First Posted Date
2024-06-28
Last Posted Date
2024-06-28
Lead Sponsor
Anhui Provincial Hospital
Target Recruit Count
39
Registration Number
NCT06480630
Locations
🇨🇳

The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, China

1 Vs 7 RATG Infusions in Renal Transplantation

Recruiting
Conditions
Kidney Replacement
Interventions
First Posted Date
2024-04-18
Last Posted Date
2024-11-28
Lead Sponsor
Mario Negri Institute for Pharmacological Research
Target Recruit Count
75
Registration Number
NCT06374095
Locations
🇮🇹

ASST HPG23 - Unità di Nefrologia, Bergamo, BG, Italy

Pediatric Induction Therapy in Kidney Transplantation

Completed
Conditions
Kidney Transplant Rejection
Pediatric Kidney Disease
Interventions
First Posted Date
2023-10-17
Last Posted Date
2023-10-17
Lead Sponsor
Gang Chen
Target Recruit Count
958
Registration Number
NCT06087003
Locations
🇨🇳

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

🇨🇳

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China

🇨🇳

The First Affiliated Hospital of Sun Yat-sen University., Guangzhou, Guangdong, China

and more 2 locations

Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement

Phase 4
Recruiting
Conditions
Safety and Efficacy
Interventions
First Posted Date
2023-10-04
Last Posted Date
2023-10-04
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
45
Registration Number
NCT06066840
Locations
🇨🇳

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies

Phase 3
Not yet recruiting
Conditions
Induction Therapy
Renal Transplant Rejection
Interventions
First Posted Date
2022-05-23
Last Posted Date
2023-09-05
Lead Sponsor
University Hospital, Tours
Target Recruit Count
244
Registration Number
NCT05385432

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

Phase 1
Recruiting
Conditions
Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia
Secondary Acute Myeloid Leukemia
Acute Myeloid Leukemia
Interventions
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Radiation: Total Lymphoid Irradiation
Radiation: Total Marrow Irradiation
First Posted Date
2021-12-01
Last Posted Date
2025-01-03
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
12
Registration Number
NCT05139004
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients

Phase 2
Conditions
SARS-CoV-2 Acute Respiratory Disease
SARS-CoV2 Infection
Cytokine Storm
Interventions
Drug: Placebo
First Posted Date
2021-08-19
Last Posted Date
2021-08-19
Lead Sponsor
Fort Worth Clinical Sciences Working Group
Target Recruit Count
300
Registration Number
NCT05013034

Standard Induction With Basiliximab Versus No-Induction in Low Immunological Risk Kidney Transplant Recipients

Phase 4
Recruiting
Conditions
Kidney Transplantation
Interventions
Other: Normal Saline
First Posted Date
2020-05-27
Last Posted Date
2021-02-18
Lead Sponsor
King Faisal Specialist Hospital & Research Center
Target Recruit Count
140
Registration Number
NCT04404127
Locations
🇸🇦

King Faisal Specialist Hospital and Research Centre (KFSHRC), Riyadh, Saudi Arabia

Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL

Phase 2
Conditions
Extranodal NK/T-cell Lymphoma
Interventions
First Posted Date
2020-04-07
Last Posted Date
2020-04-07
Lead Sponsor
Beijing Tongren Hospital
Target Recruit Count
20
Registration Number
NCT04337593

Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant

Phase 4
Completed
Conditions
Asses Immunosuppression Modulation on Renal Recovery Post LT
Interventions
First Posted Date
2019-09-26
Last Posted Date
2025-04-23
Lead Sponsor
Fady M Kaldas, M.D., F.A.C.S.
Target Recruit Count
71
Registration Number
NCT04104438
Locations
🇺🇸

UCLA Medical Center, Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy